Portfolio at a glance
Securities as at June 30, 2023
|
Company |
|
Number of securities |
|
Change since 31.12.2022 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
9 299 700 |
|
(335 300) |
|
USD |
|
41.03 |
|
341.7 |
|
13.3% |
|
15.1% |
|
6.5% |
|
Argenx SE |
|
865 000 |
|
(27 503) |
|
USD |
|
389.73 |
|
301.9 |
|
11.7% |
|
13.3% |
|
1.6% |
|
Vertex Pharmaceuticals |
|
850 000 |
|
(80 523) |
|
USD |
|
351.91 |
|
267.9 |
|
10.4% |
|
11.8% |
|
0.3% |
|
Neurocrine Biosciences |
|
2 590 000 |
|
(140 000) |
|
USD |
|
94.30 |
|
218.7 |
|
8.5% |
|
9.7% |
|
2.7% |
|
Intra-Cellular Therapies |
|
3 150 000 |
|
(141 479) |
|
USD |
|
63.32 |
|
178.6 |
|
6.9% |
|
7.9% |
|
3.3% |
|
Moderna |
|
1 475 000 |
|
(26 951) |
|
USD |
|
121.50 |
|
160.5 |
|
6.2% |
|
7.1% |
|
0.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alnylam Pharmaceuticals |
|
875 000 |
|
(15 000) |
|
USD |
|
189.94 |
|
148.8 |
|
5.8% |
|
6.6% |
|
0.7% |
|
Incyte |
|
2 617 000 |
|
(274 077) |
|
USD |
|
62.25 |
|
145.9 |
|
5.7% |
|
6.4% |
|
1.2% |
|
Sage Therapeutics |
|
3 080 000 |
|
129 722 |
|
USD |
|
47.02 |
|
129.7 |
|
5.0% |
|
5.7% |
|
5.2% |
|
Revolution Medicines |
|
4 675 000 |
|
(102 562) |
|
USD |
|
26.75 |
|
112.0 |
|
4.4% |
|
5.0% |
|
4.4% |
|
Agios Pharmaceuticals |
|
4 000 000 |
|
(30 792) |
|
USD |
|
28.32 |
|
101.5 |
|
3.9% |
|
4.5% |
|
7.2% |
|
Celldex Therapeutics |
|
1 800 000 |
|
– |
|
USD |
|
33.93 |
|
54.7 |
|
2.1% |
|
2.4% |
|
3.8% |
|
Arvinas |
|
2 120 000 |
|
(16 412) |
|
USD |
|
24.82 |
|
47.1 |
|
1.8% |
|
2.1% |
|
4.0% |
|
Relay Therapeutics |
|
4 100 000 |
|
(20 720) |
|
USD |
|
12.56 |
|
46.1 |
|
1.8% |
|
2.0% |
|
3.4% |
|
Macrogenics |
|
9 579 963 |
|
650 000 |
|
USD |
|
5.35 |
|
45.9 |
|
1.8% |
|
2.0% |
|
15.5% |
|
Crispr Therapeutics |
|
880 000 |
|
(8 605) |
|
USD |
|
56.14 |
|
44.2 |
|
1.7% |
|
2.0% |
|
1.1% |
|
Exelixis |
|
2 525 000 |
|
(129 500) |
|
USD |
|
19.11 |
|
43.2 |
|
1.7% |
|
1.9% |
|
0.8% |
|
Black Diamond Therapeutics |
|
8 117 839 |
|
2 740 000 |
|
USD |
|
5.05 |
|
36.7 |
|
1.4% |
|
1.6% |
|
15.8% |
|
Fate Therapeutics |
|
4 839 779 |
|
– |
|
USD |
|
4.76 |
|
20.6 |
|
0.8% |
|
0.9% |
|
4.9% |
|
Beam Therapeutics |
|
693 121 |
|
– |
|
USD |
|
31.93 |
|
19.8 |
|
0.8% |
|
0.9% |
|
0.9% |
|
Essa Pharma |
|
7 879 583 |
|
– |
|
USD |
|
2.70 |
|
19.1 |
|
0.7% |
|
0.8% |
|
17.9% |
|
Generation Bio Co. |
|
3 608 280 |
|
– |
|
USD |
|
5.50 |
|
17.8 |
|
0.7% |
|
0.8% |
|
5.5% |
|
Rivus Pharmaceuticals 1) |
|
|
|
|
|
USD |
|
|
|
15.7 |
|
0.6% |
|
0.7% |
|
|
|
Mersana Therapeutics |
|
5 205 925 |
|
1 139 725 |
|
USD |
|
3.29 |
|
15.3 |
|
0.6% |
|
0.7% |
|
4.6% |
|
Wave Life Sciences |
|
4 494 458 |
|
– |
|
USD |
|
3.64 |
|
14.7 |
|
0.6% |
|
0.6% |
|
4.6% |
|
Scholar Rock Holding |
|
2 132 725 |
|
– |
|
USD |
|
7.54 |
|
14.4 |
|
0.6% |
|
0.6% |
|
3.9% |
|
Esperion Therapeutics |
|
4 194 064 |
|
– |
|
USD |
|
1.39 |
|
5.2 |
|
0.2% |
|
0.2% |
|
4.4% |
|
Molecular Templates |
|
11 192 003 |
|
– |
|
USD |
|
0.48 |
|
4.8 |
|
0.2% |
|
0.2% |
|
19.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Radius Health – Contingent Value Right |
|
8 733 538 |
|
– |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
2 572.7 |
|
100.0% |
|
113.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
5.7 |
|
|
|
0.3% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(316.0) |
|
|
|
(14.0%) |
|
|
|
Net Asset Value |
|
|
|
|
|
|
|
|
|
2 262.5 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1) Unlisted company
Exchange rate as at 30.06.2023: USD/CHF: 0.8956